OBSIDIAN THERAPEUTICS INC
OBXNASDAQTrading Snapshot
- Day Range
- $14.60 โ $15.87
- 52-Week Range
- $11.52 โ $49.97
- Volume (shares)
- 52,006.439
- Avg Volume (shares)
- โ
- Shares Outstanding
- 61.8M
- Next Earnings
- โ
Fundamentals Snapshot
- Annual Revenue
- โ
- Last Q Revenue
- โ
- P/E Ratio
- โ
- P/S Ratio
- โ
- EPS (TTM)
- โ
- Dividend Yield
- โ
OBSIDIAN THERAPEUTICS INC
OBXFinancial history unavailable.
StockOtter ยท stockotter.spaceAbout OBSIDIAN THERAPEUTICS INC
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVEยฎ technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
โLatest News & Updates
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
Obsidian Therapeutics, Inc. (รขยยObsidianรขยย) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop
Obsidian Therapeutics (NASDAQ:OBX) Short Interest Update
Obsidian Therapeutics (NASDAQ: OBX - Get Free Report) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 253,084 shares, a growth o
Obsidian Therapeutics: A $1.1 Billion Valuation Leaves Little Margin For Error
Obsidian Therapeutics is rated Hold due to overvaluation despite promising cell therapy technology targeting solid tumors. OBX-115, the lead asset, shows strong early efficacy and safety in advanced melanoma, but is only
Here Are Thursdayโs Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment befo
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (โObsidianโ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltratin
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (โObsidianโ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltratin